, Volume 106, Supplement 1, pp S127–S129 | Cite as

Safety of moclobemide taken in overdose for attempted suicide

  • W. Hetzel
Section V Special Patient Groups Mini-Paper


Moclobemide is a reversible inhibitor of the monoamine oxidase type A. In clinical studies, more than 3900 patients have been treated with moclobemide for depression. Eighteen of these patients attempted suicide by overdosing moclobemide with or without other drugs. All patients recovered fully without leaving signs of cardio-or hepatotoxicity. Moclobemide can safely be prescribed for in- and out-patient treatment of depression.

Key words

Moclobemide MAO-A inhibitor Overdose 


  1. Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 28:21–31Google Scholar
  2. Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. Br Med J 295:1021–1024Google Scholar
  3. Da Prada M et al. (1989) Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl 28:5–20Google Scholar
  4. Pöldinger W (1987) Incidence and evaluation of risk of suicide in depression. In: Bizière K, Garratini S, Simon P (eds) Proceedings of Symposium ‘Quo vadis?’: diagnosis and treatment of depression, May 11–12, 1987, Montpellier, FranceGoogle Scholar
  5. Versiani M et al. (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand Suppl 82:29–34Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • W. Hetzel
    • 1
  1. 1.Pharma Clinical Research DepartmentF. Hoffmann-La Roche LtdBaselSwitzerland

Personalised recommendations